CABOZANTINIB AND NIVOLUMAB REGISTER BETTER THAN EXPECTED RESULTS IN CLINICAL TRIALS FOR KIDNEY CANCER
CABOZANTINIB AND NIVOLUMAB REGISTER BETTER THAN EXPECTED RESULTS IN CLINICAL TRIALS FOR KIDNEY CANCER
@ In two separate clinical trials supported by pharmaceutical major Bristol Myers Squibb, researchers have found better survival rates for patients suffering from Kidney Cancer with nivolumab and cabozantinib .// Nivolumab is among a new class of drugs termed as immune checkpoint inhibitor .// These drugs improve body*s immune system to fight against cancer cells .//
@ Nivolumab is already sold in the market under brand name Opdivo for lung cancer and advanced skin cancer patients .// In the clinical trial, 821 patients suffering from advanced stage kidney cancer were given Nivolumab instead of Everolimus .// ©Nivolumab enhances body*s defense against cancer cells .//
@ The study team found that patients given Nivolumab had increased survival rate at 25 months compared to 19 .//6 months average with everolimus .// The study ended before its scheduled completion as the results were better than expected .// The study team found that the drug had much better tumor response rate compared to everolimus .//
@ In the second clinical trial, cabozantinib was tested for kidney cancer patients .// Cabozantinib was tested for its efficacy against everolimus .// ©Cabozantinib was tested for survival of kidney cancer patients and its effectiveness in stopping the progression of cancer .//
@ In the second trial, average survival rate increased from 3 .//8 months with standard kidney cancer therapy to 7 .//4 months with cabozantinib .//